drugset / Trial / NCT02802423
Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.
NaSingle-groupOpen-labelTreatment
Summary
The primary purpose of this study is to determine the safety and recommended dose level (RDL) of BLEX 404 Oral Liquid combined with Docetaxel monotherapy in a 21-day schedule. The secondary purpose is to assess the efficacy and safety of BLEX 404 Oral Liquid combined with Docetaxel monotherapy.
Timeline
- Start
- 2027-01-01
- Primary completion
- 2028-04-30
- Completion
- 2028-08-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BLEX 404 | Unknown | 3 mg/kg | Oral |
| Subject | BLEX 404 | Unknown | 10 mg/kg | Oral |